- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 368075, 8 pages
-Labeled Cystine-Knot Peptides Based on the Agouti-Related Protein for Targeting Tumor Angiogenesis
1Department of Nuclear Medicine, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University, Shanghai 200233, China
2Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford Cancer Institute, and Bio-X Program, Canary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, CA 94305, USA
3Department of Bioengineering, Stanford Cancer Institute, and Bio-X Program, Stanford University, Stanford, CA 94305, USA
Received 14 December 2011; Revised 29 January 2012; Accepted 30 January 2012
Academic Editor: David J. Yang
Copyright © 2012 Lei Jiang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- T. Saga, M. Koizumi, T. Furukawa, K. Yoshikawa, and Y. Fujibayashi, “Molecular imaging of cancer—evaluating characters of individual cancer by PET/SPECT imaging,” Cancer Science, vol. 100, no. 3, pp. 375–381, 2009.
- R. Weissleder and U. Mahmood, “Molecular imaging,” Radiology, vol. 219, no. 2, pp. 316–333, 2001.
- T. F. Massoud and S. S. Gambhir, “Molecular imaging in living subjects: seeing fundamental biological processes in a new light,” Genes and Development, vol. 17, no. 5, pp. 545–580, 2003.
- S. Mather, “Molecular imaging with bioconjugates in mouse models of cancer,” Bioconjugate Chemistry, vol. 20, no. 4, pp. 631–643, 2009.
- W. A. Weber, “Positron emission tomography as an imaging biomarker,” Journal of Clinical Oncology, vol. 24, no. 20, pp. 3282–3292, 2006.
- H. Kolmar, “Biological diversity and therapeutic potential of natural and engineered cystine knot miniproteins,” Current Opinion in Pharmacology, vol. 9, no. 5, pp. 608–614, 2009.
- H. Kolmar, “Alternative binding proteins: biological activity and therapeutic potential of cystine-knot miniproteins,” FEBS Journal, vol. 275, no. 11, pp. 2684–2690, 2008.
- A. P. Silverman, A. M. Levin, J. L. Lahti, and J. R. Cochran, “Engineered cystine-knot peptides that bind integrin with antibody-like affinities,” Journal of Molecular Biology, vol. 385, no. 4, pp. 1064–1075, 2009.
- R. O. Hynes, “Integrins: versatility, modulation, and signaling in cell adhesion,” Cell, vol. 69, no. 1, pp. 11–25, 1992.
- R. E. B. Seftor, E. A. Seftor, K. R. Gehlsen et al., “Role of the integrin in human melanoma cell invasion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 5, pp. 1557–1561, 1992.
- P. C. Brooks, R. A. F. Clark, and D. A. Cheresh, “Requirement of vascular integrin for angiogenesis,” Science, vol. 264, no. 5158, pp. 569–571, 1994.
- E. Chang, S. Liu, G. Gowrishankar et al., “Reproducibility study of [18F]FPP(RGD)2 uptake in murine models of human tumor xenografts,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 4, pp. 722–730, 2011.
- L. Jiang, R. H. Kimura, Z. Miao et al., “Evaluation of a 64Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing integrin,” Journal of Nuclear Medicine, vol. 51, no. 2, pp. 251–258, 2010.
- J. Yang, H. Guo, and Y. Miao, “Technetium-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging,” Nuclear Medicine and Biology, vol. 37, no. 8, pp. 873–883, 2010.
- Z. Xiong, Z. Cheng, X. Zhang et al., “Imaging chemically modified adenovirus for targeting tumors expressing integrin in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene,” Journal of Nuclear Medicine, vol. 47, no. 1, pp. 130–139, 2006.
- Z. Cheng, J. Chen, T. P. Quinn, and S. S. Jurisson, “Radioiodination of rhenium cyclized α-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma,” Cancer Research, vol. 64, no. 4, pp. 1411–1418, 2004.
- M. Bäckberg, N. Madjid, S. O. Ögren, and B. Meister, “Down-regulated expression of agouti-related protein (AGRP) mRNA in the hypothalamic arcuate nucleus of hyperphagic and obese tub/tub mice,” Molecular Brain Research, vol. 125, no. 1-2, pp. 129–139, 2004.
- J. R. Shutter, M. Graham, A. C. Kinsey, S. Scully, R. Lüthy, and K. L. Stark, “Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice,” Genes and Development, vol. 11, no. 5, pp. 593–602, 1997.
- M. M. Ollmann, B. D. Wilson, Y. K. Yang et al., “Antagonism of Central Melanocortin receptors in vitro and in vivo by agouti-related protein,” Science, vol. 278, no. 5335, pp. 135–138, 1997.
- P. J. Jackson, J. C. McNulty, Y. K. Yang et al., “Design, pharmacology, and NMR structure of a minimized cystine knot with agouti-related protein activity,” Biochemistry, vol. 41, no. 24, pp. 7565–7572, 2002.
- P. J. Jackson, N. R. Douglas, B. Chai et al., “Structural and molecular evolutionary analysis of Agouti and Agouti-related proteins,” Chemistry and Biology, vol. 13, no. 12, pp. 1297–1305, 2006.
- S. R. Kumar and S. L. Deutscher, “111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors,” Journal of Nuclear Medicine, vol. 49, no. 5, pp. 796–803, 2008.
- C. E. Mogensen and K. Solling, “Studies on renal tubular protein reabsorption: partial and near complete inhibition by certain amino acids,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 37, no. 6, pp. 477–486, 1977.
- S. Silbernagl, “The renal handling of amino acids and oligopeptides,” Physiological Reviews, vol. 68, no. 3, pp. 911–1007, 1988.
- J. Q. Chen, Z. Cheng, N. K. Owen et al., “Evaluation of an 111In-DOTA-rhenium cyclized α-MSH analog: a novel cyclic-peptide analog with improved tumor-targeting properties,” Journal of Nuclear Medicine, vol. 42, no. 12, pp. 1847–1855, 2001.
- J. Q. Chen, Z. Cheng, T. J. Hoffman, S. S. Jurisson, and T. P. Quinn, “Melanoma-targeting properties of 99mtechnetium-labeled cyclic α-melanocyte-stimulating hormone peptide analogues,” Cancer Research, vol. 60, no. 20, pp. 5649–5658, 2000.
- L. Jiang, Z. Miao, R. H. Kimura et al., “Preliminary evaluation of 177Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 38, no. 4, pp. 613–622, 2011.
- M. Yoshimoto, K. Ogawa, K. Washiyama et al., “ integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide,” International Journal of Cancer, vol. 123, no. 3, pp. 709–715, 2008.
- M. L. Janssen, W. J. Oyen, I. Dijkgraaf et al., “Tumor targeting with radiolabeled integrin binding peptides in a nude mouse model,” Cancer Research, vol. 62, no. 21, pp. 6146–6151, 2002.